Cancer Research Families Face Uncertainty as Federal Funding Changes

Five-year-old Juliette Lesko’s fight against ependymoma, a rare brain cancer, has become increasingly complicated. After enduring multiple surgeries, extensive radiation treatment, and two cancer recurrences over two years, she now depends on an experimental medication with uncertain results.

Her father, Jim Lesko, anxiously awaits upcoming brain imaging results that will determine whether the current treatment remains effective. Should the scans reveal tumor growth, the family will need to pursue alternative therapies immediately.

However, their plans hit an unexpected obstacle when a promising clinical trial in Texas suddenly ceased patient enrollment. This particular study, conducted through the Pediatric Brain Tumor Consortium (PBTC), represented a crucial treatment option for children with Juliette’s specific cancer type.

The PBTC has served as a vital national network connecting leading medical experts, researchers, and healthcare facilities for 25 years. Through this consortium, families gained access to cutting-edge experimental treatments via clinical trials. This changed dramatically in August when the National Cancer Institute announced it would discontinue funding for the program.

Widespread Research Disruption

The funding termination reflects broader challenges affecting cancer research and federal science programs. Significant reductions in National Institutes of Health grants, substantial staff departures, and leadership gaps at the National Cancer Institute have created widespread concern among researchers about setbacks that could last for years.

Department of Health and Human Services representatives defended the decision, stating that eliminating PBTC funding would enable more efficient resource allocation. They announced plans to transfer existing clinical trials to another pediatric cancer network, promising to enhance research capacity and streamline development processes.
Despite official assurances, over ten pediatric oncologists, scientists, and cancer advocates expressed deep concern about this decision’s impact on an already underfunded pediatric cancer research community.

Dr. Eugene Hwang, a pediatric neuro-oncologist at Children’s National Hospital, described the prevailing mood as one of despair. He emphasized that pediatric brain cancer research has become more challenging not due to worsening disease characteristics, but because of diminished research capabilities.

Six PBTC clinical trials have suspended new patient enrollment, affecting studies for innovative immunotherapies and medical devices designed to disrupt cancer cell division. Approximately 200 potential participants may lose access to these suspended trials, with only 15 patients currently enrolled able to continue their treatment.

Budget Constraints Intensify Challenges

The National Cancer Institute’s budget restrictions have created additional barriers. Research proposals scoring in the top 7% during grant evaluations—typically guaranteed funding—now compete for resources limited to only the top 4% of applications.

Dr. Hwang’s promising brain cancer vaccine, which demonstrated effectiveness against aggressive tumors in laboratory studies, faces funding uncertainty despite strong scientific merit. Over 1,000 families and advocates have written letters supporting this research, emphasizing its life-saving potential.

Organizational disruption at the National Cancer Institute, including staff departures and reduced patient recruitment, has further complicated the research landscape. Clinical center data shows declining patient numbers, attributed to scientist exodus and recruitment challenges.

Administrative Policy Impacts

Federal grant suspensions targeting diversity and inclusion programs have affected pediatric cancer research. Studies examining chemotherapy-related heart failure risks and childhood leukemia patterns in specific populations have lost funding due to policy changes.

International research collaboration restrictions particularly impact rare disease studies, where small patient populations require global cooperation to achieve meaningful sample sizes.

For families like the Leskos, these policy shifts create frustration and diminished hope. Despite presidential acknowledgment of childhood cancer as a national priority, actual research support appears to be declining.
The National Brain Tumor Society plans to submit a petition with over 1,000 signatures requesting reconsideration of the PBTC funding decision, reflecting widespread community concern about these changes.